Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Measles - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Measles - Pipeline Review, H2 2016, provides an overview of the Measles (Infectious Disease) pipeline landscape. Measles is a highly infectious viral disease. The virus lives in the mucus of the nose and throat of people with this infection. Physical contact, coughing and sneezing can spread the infection. Symptoms of measles are high temperature, sore eyes (conjunctivitis), and a runny nose usually occur first, small white spots usually develop inside the mouth a day or so later, diarrhea and vomiting. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Measles - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Measles (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Measles (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Measles and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 2, 1, 4 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively for Measles. Measles (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Measles (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Measles (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Measles (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Measles (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Measles (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Measles (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Measles (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Measles Overview 7 Therapeutics Development 8 Pipeline Products for Measles - Overview 8 Pipeline Products for Measles - Comparative Analysis 9 Measles - Therapeutics under Development by Companies 10 Measles - Therapeutics under Investigation by Universities/Institutes 11 Measles - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Measles - Products under Development by Companies 15 Measles - Products under Investigation by Universities/Institutes 16 Measles - Companies Involved in Therapeutics Development 17 Beijing Minhai Biotechnology Co., Ltd 17 Beijing Tiantan Biological Products Co., Ltd. 18 Biological E. Limited 19 Daiichi Sankyo Company, Limited 20 GlaxoSmithKline Plc 21 Prometheon Pharma, LLC 22 Sinovac Biotech Ltd. 23 VBI Vaccines Inc 24 Vical Incorporated 25 Zydus Cadila Healthcare Limited 26 Measles - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 (measles + mumps + rubella + varicella) vaccine - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 (measles + mumps + rubella) vaccine - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 (measles + mumps + rubella) vaccine - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 (measles + mumps + rubella) vaccine - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 (measles + rubella + varicella) vaccine - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 (measles + rubella) vaccine - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 (measles + rubella) vaccine - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 ERDRP-0519 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 measles (bivalent) vaccine - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 measles + mumps + rubella + varicella vaccine - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 measles vaccine - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 measles vaccine - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 VN-0102 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Measles - Dormant Projects 50 Measles - Product Development Milestones 51 Featured News & Press Releases 51 Aug 21, 2008: Vaxfectin Formulated Measles DNA Vaccine Could Address Unmet Need for Infants 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Measles, H2 2016 8 Number of Products under Development for Measles - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Measles - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 17 Measles - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016 18 Measles - Pipeline by Biological E. Limited, H2 2016 19 Measles - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 20 Measles - Pipeline by GlaxoSmithKline Plc, H2 2016 21 Measles - Pipeline by Prometheon Pharma, LLC, H2 2016 22 Measles - Pipeline by Sinovac Biotech Ltd., H2 2016 23 Measles - Pipeline by VBI Vaccines Inc, H2 2016 24 Measles - Pipeline by Vical Incorporated, H2 2016 25 Measles - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 26 Assessment by Monotherapy Products, H2 2016 27 Assessment by Combination Products, H2 2016 28 Number of Products by Stage and Target, H2 2016 30 Number of Products by Stage and Mechanism of Action, H2 2016 31 Number of Products by Stage and Route of Administration, H2 2016 33 Number of Products by Stage and Molecule Type, H2 2016 35 Measles - Dormant Projects, H2 2016 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.